Immune checkpoint blockade (ICB) agents, such as those targeting CTLA-4 or programmed death (PD)-1, are designed to improve the ability of CD8+ T lymphocytes to maintain effector function and kill tumor targets. This evidence concerns the gene CD8A and neoplasm.